Literature DB >> 8782689

Taxonomic study of lancefield streptococcal groups C, G, and L (Streptococcus dysgalactiae) and proposal of S. dysgalactiae subsp. equisimilis subsp. nov.

P Vandamme1, B Pot, E Falsen, K Kersters, L A Devriese.   

Abstract

Streptococcus dysgalactiae consists of at least five distinct subgroups on the basis of serogroups, biotypes, and hosts. A chemotaxonomic and phenotypic examination of 80 S. dysgalactiae strains representing the known diversity within this species and 49 reference strains representing all members of the streptococcal pyogenic species group revealed two subpopulations of strains within S. dysgalactiae. The name S. dysgalactiae subsp. dysgalactiae is proposed for strains of animal origin. These strains belong to Lancefield serogroups C and L, are alpha-, beta-, or nonhemolytic, and do not exhibit streptokinase activity on human plasminogen or proteolytic activity on human fibrin. The name S. dysgalactiae subsp. equisimilis is proposed for human isolates. These strains belong to Lancefield serogroups C and G, are beta-hemolytic, and exhibit streptokinase activity on human plasminogen and proteolytic activity on human fibrin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782689     DOI: 10.1099/00207713-46-3-774

Source DB:  PubMed          Journal:  Int J Syst Bacteriol        ISSN: 0020-7713


  57 in total

1.  Delineation of Streptococcus dysgalactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes.

Authors:  Anders Jensen; Mogens Kilian
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Identification of major Streptococcal species by rrn-amplified ribosomal DNA restriction analysis.

Authors:  Laurent Schlegel; Francine Grimont; Patrick A D Grimont; Anne Bouvet
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  Prevalence and mechanism of resistance to antimicrobial agents in group G streptococcal isolates from China.

Authors:  Jun Yin; Sangjie Yu; Xiaorong Liu; Ye Li; Wei Gao; Xiang Ma; Yonghong Yang
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

4.  Directional gene movement from human-pathogenic to commensal-like streptococci.

Authors:  A Kalia; M C Enright; B G Spratt; D E Bessen
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 5.  Streptococcus dysgalactiae subsp. equisimilis bacteremia: an emerging infection.

Authors:  S Rantala
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-29       Impact factor: 3.267

6.  Phage 3396 from a Streptococcus dysgalactiae subsp. equisimilis pathovar may have its origins in streptococcus pyogenes.

Authors:  Mark R Davies; David J McMillan; Gary H Van Domselaar; Malcolm K Jones; Kadaba S Sriprakash
Journal:  J Bacteriol       Date:  2007-01-26       Impact factor: 3.490

7.  Clonal relationships between invasive and noninvasive Lancefield group C and G streptococci and emm-specific differences in invasiveness.

Authors:  M D Pinho; J Melo-Cristino; M Ramirez
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 8.  Use of enzyme tests in characterization and identification of aerobic and facultatively anaerobic gram-positive cocci.

Authors:  S Bascomb; M Manafi
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

9.  Analysis of a viridans group strain reveals a case of bacteremia due to lancefield group G alpha-hemolytic Streptococcus dysgalactiae subsp equisimilis in a patient with pyomyositis and reactive arthritis.

Authors:  Patrick C Y Woo; Jade L L Teng; Susanna K P Lau; Peggy N L Lum; Kit-Wah Leung; Kee-Lam Wong; Kin-Wah Li; Kui-Chun Lam; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  Septicemia and meningitis due to Streptococcus zooepidemicus.

Authors:  M Ferrandière; B Cattier; P F Dequin; E Hazouard; A Legras; D Perrotin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.